KIT or a-platelet-derived growth factor receptor (a-PDGFR) activating mutations are the pathogenic mechanisms that characterize gastrointestinal stromal tumors (GIST). Despite excellent responses to imatinib mesylate (IM), patients are relapsing. We developed an IM-resistant GIST cell line (GIST-R) from the IMsensitive GIST882 cell line (GIST-S) by growing these cells in IM. Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance. Instead, GIST-R cells have acquired IM resistance by overexpressing the oncogenic receptor tyrosine kinase -AXL -in a 'kinase switch'. Further, the two IM resistant GIST patients express AXL and not c-Kit, seen by immunohistochemistry (IHC). Real time reverse transcriptase-polymerase chain reaction and Western blotting of the GIST-S and GIST-R cells confirmed the switch from Kit to AXL. In GIST-R, AXL is tyrosine phosphorylated and its ligand growtharrest-specific gene 6 is overexpressed implying autocrine activation. The kinase switch is associated with a morphological change from spindle to epithelioid. Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor. MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.
Introduction
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors of the gastrointestinal tract and are most commonly found in the stomach (B60%), small intestine (B25%), rectum (5%) and esophagus (3%) (Dematteo et al., 2000) . GIST are believed to have derived from interstitial cells of Cajal, the pacemaker cells of the gut (Perez-Atayde et al., 1993) and are recognized as spindle type (70%), epithelioid (20%) or mixed with c-Kit expression in virtually all cases. Other markers of importance but of variable expression are Bcl-2 (80%), CD34 (70%), muscle-specific actin (50%), smooth muscle actin (35%), S-100 (10%) and desmin (5%) (Corless et al., 2004) . KIT (CD117) , an oncogenic receptor tyrosine kinase (RTK), is structurally homologous to platelet-derived growth factor receptor (PDGFR), fetal liver tyrosine kinase 3 and macrophage colony-stimulating factor receptor. It is 145 kDa, activated upon dimerization with its ligand stem cell factor and leads to amplification of signaling cascades that include phosphatidyl inositol (PI)-3K/Akt/mTor necessary for proliferation, antiapoptosis, adhesion and differentiation (Corless et al., 2004) . In GIST, a gain-of-function mutation in Kit results in constitutive activation of the protein tyrosine kinase and its downstream signaling pathways (Hirota et al., 1998) . These mutations are found in exon 11 (B66%), which encodes the juxta-membrane domain, and less often in exons 9 (B13%), 13 (B1.0%) and 17 (B0.6%). A subset of GIST has mutations in the a-PDGFR, which occurs in either exon 18 (B5.6%) or 12 (B1.5%). The remainder (B10-12%) is wild type (WT) for both KIT and a-PDGFR (Corless et al., 2004) . Genetic analysis of GIST with varying exon 11 mutations shows a similar genetic profile (Kitamura and Hirotab, 2004) .
Before 2000, surgery was the only successful treatment option for GIST, provided the tumor was resectable. However, radiation and chemotherapy provide a o10% response rate (Dematteo et al., 2000 (Dematteo et al., , 2002 . Imatinib mesylate (IM), an orally administered selective c-Kit/PDGFR tyrosine kinase inhibitor, abrogates cellular proliferation of GIST cells in culture (Tuveson et al., 2001) and inhibits the constitutively active phosphorylating activity of c-Kit and PDGFR by binding the adenosine 5 0 -trisphosphate (ATP) site preventing the activation of PI-3K and mitogenactivated protein kinase dependent pathways (Heinrich et al., 2003) . A randomized trial of GIST patients treated with IM showed that 5% patients achieved a complete response, 47% partial response and 32% stable disease (Verweij et al., 2004) .
Patients with GIST treated with IM are developing resistance. Five potential resistance mechanisms are: functional resistance (exon 9 and WT KIT); genomic amplification and KIT overexpression (Bauer et al., 2005) ; acquisition of secondary mutations (e.g. V654A) (Chen et al., 2004) ; activation of alternate RTKs (Mahadevan et al., 2005a) ; and ATP-dependent IM efflux through ABCB1/ABCC1 transporters (Theou et al., 2005) . Our strategy was to develop an IM-resistant GIST cell line and perform gene expression profiling (GEP) on GIST-S and GIST-R cells to identify marker(s) of IM resistance. We demonstrate that KIT expression is >100-fold downregulated in GIST-R whereas AXL, an alternate RTK, is B 49-fold and c-Met B 19-fold overexpressed. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting confirmed the Kit to AXL/c-Met 'kinase switch'. Two IM-resistant GIST patients showed loss of c-Kit expression and gain of AXL expression by GEP, RT-PCR and immunohistochemistry (IHC). Homology models of mutant c-Kit (V654A) and AXL tyrosine kinase domains showed no IM binding; MP470, a novel c-Kit/AXL/cMet tyrosine kinase inhibitor, bound efficiently. MP470 alone was cytotoxic to GIST cells and was synergistic with taxotere (docetaxel).
Results

Development of an IM-resistant GIST882 cell line (GIST-R)
GIST-S cells were utilized to develop a GIST-R cell line by stepwise dial-up of the IM concentration. At each IM concentration 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed to ascertain IM sensitivity/resistance by calculating the biological IC 50 values. MTT results are shown for GIST-S and GIST-R cells (0.5 mM IM) treated with IM (0.05-50 mM) (Figure 1a ). The IC 50 values (0.1-0.3 mM) were essentially unchanged for GIST-S and GIST882 cells continuously growing at 0.1, 0.2 and 0.3 mM IM (data not shown). However, the IC 50 dramatically changed to >1 mM once the GIST cells were growing in 0.5 mM IM (Figure 1a) . Hence, there was an abrupt onset of IM resistance in GIST-R owing to new mutations and/or overexpression of KIT or alternate evolution of a novel mechanism(s) of resistance such as loss of c-Kit and/or acquisition of a novel tyrosine kinase.
A tyrosine kinase switch contributes to IM resistance in GIST To study the observations in Figure 1a , a GEP study was performed that compared GIST-S with GIST-R cells (Table 1) and two IM-resistant GIST patients. The GEP demonstrated that the expression of KIT was undetectable in the GIST-R cell line (>100-fold downregulated) or patient's samples (>100-fold downregulated), whereas AXL tyrosine kinase was overexpressed by 49-fold (GIST-R), 11-fold (two GIST patients) and c-Met by 19-fold (GIST-R). This was confirmed by realtime RT-PCR with KIT and AXL-specific probes for the GIST cell lines and patient samples ( Figure 1b) and by Western blotting for c-Kit and AXL expression and AXL tyrosine phosphorylation for the GIST cell lines (Figure 1c ). These data demonstrate loss of expression of KIT at the mRNA and protein level in the GIST-R cells. A gain of expression of AXL is observed at the mRNA level (>100-fold) and protein level (>three-fold) in the GIST-R cells. Hence, AXL and c-Met (data Imatinib resistance in gastrointestinal stromal tumors D Mahadevan et al not shown) appear to replace KIT as the predominant RTK. Moreover, in GIST-R cells AXL is tyrosinephosphorylated implying an active RTK, thus maintaining a proliferative signal despite IM. Furthermore, growth-arrest-specific gene 6 (GAS-6), the ligand for AXL, is 6-fold and hepatocyte growth factor (HGF), the ligand for c-Met, is 14-fold overexpressed indicating a dual autocrine mechanism for cell proliferation. IHC analysis of the two IM-resistant GIST patients for c-Kit and AXL did not demonstrate c-Kit expression, but demonstrated strong AXL expression confirming and validating the cell culture data (Figure 1d ). These results provide credence to the observation that a KIT to AXL kinase switch also occurs in IM-resistant GIST patients.
Other differentially expressed genes in GIST-R cells include CXCL14 (121-fold), CD24 (115-fold), PDGF-CC (66-fold), SERPINE2 (54-fold) and BMP and activin membrane-bound inhibitor (BAMBI) (43-fold). The overexpression of a multitude of cancer-associated protein in GIST-R appears to provide a growth advantage.
A morphological change accompanies IM resistance During cell culture of GIST-S and GIST cell lines exposed to IM (0.1, 0.2, 0.3 and 0.5 mM), a morphological change was observed in the GIST-R cell line (0.5 mM, IM) ( Figure 2a ) and this appears to correlate with the kinase switch ( Figure 2b ). The GIST-S and GIST growing in IM (0.1, 0.2 and 0.3 mM) have spindleshaped morphology when grown to confluence. Postconfluent cell cultures of GIST-S and GIST-R (IM at 0.5 mM) cells displayed distinct morphologies. Abbreviation: GIST, gastrointestinal stromal tumors.
Imatinib resistance in gastrointestinal stromal tumors D Mahadevan et al
The GIST-S cell line was morphologically homogeneous consisting of closely packed elongated cells producing a culture with a swirled appearance. In contrast, the GIST-R cell line was heterogeneous in appearance consisting of subpopulations of tightly packed patches of flat epithelioid cells interspersed with elongated cells. Over time, the epithelioid patches increased in size and coalesced to occupy an increasing proportion of the total cell culture. GEP showed differential expression of cytoskeletal (Myosin X, Fascin homolog 1, Elfin, Topomyosin 2, ELMO1), cell adhesion (Cadherin-6, NEDD9, VLA-3, SPP1) and extracellular matrix (ECM) proteins (SPARC, MMP3, TFPI2, CTGF, MMP2) ( Table 2 ) are hypothesized to contribute to the GIST-R phenotype.
MP470 is a c-Kit/AXL tyrosine kinase inhibitor MTT assays performed on the GIST-S cell line with MP470 (0.25-11 mM) demonstrate IC 50 values of 0.3-0.5 mM. MP470 had an IC 50 of 2 mM in the GIST-R cell line ( Figure 3a ) indicating that MP470 acts as an AXL kinase inhibitor. We utilized the MDA-MB-231 breast cancer cell line (as an independent positive control) that overexpresses an active tyrosine phosphorylated AXL (Holland et al., 2005) to evaluate the efficacy of MP470 to inhibit its phosphorylation. Western blotting analysis shows inhibition of tyrosine phosphorylation of AXL by MP470 at 1.0 mM ( Figure 3b ) and is in the range observed for the GIST-R cells ( Figure 2a ). Western blotting analysis with an anti-c-Kit antibody and antiphosphotyrosine antibody showed that both IM and MP470 inhibit c-Kit phosphorylation in GIST-S cells without affecting the c-Kit protein levels ( Figure 3c ). These data support the observation that MP470 is a c-Kit/AXL tyrosine kinase inhibitor.
Docetaxel synergizes with MP470 to induce cell death in GIST-S cells GIST-S cells treated with docetaxel in a MTT assay did not reach IC 50 but the drug concentration at which 50% 
Genes induced by MP470 in the GIST-S and GIST-R cell lines
The GEP of MP470-treated GIST-S cells differentially expressed HSPA6 (47-fold), GDF15 (12-fold), CXCL12 (ninefold), GADD45B (ninefold), CYR61 (eightfold), MAFF (eightfold), superoxide dismutase 2 (SOD2) (fivefold) and DUSP1 (fivefold) (Table 3A) , which are involved in cellular response to environmental stresses. In contrast, treatment of GIST-R cells with MP470 induced genes including IL-8 (8.5-fold), CXCL11 (eightfold), CXCL6 (eightfold), CXCL3 (7.5-fold), CXCL5 (sevenfold), CXCL10 (6.5-fold), CXCL1 (sixfold) and VCAM-1 (fivefold) (Table 3B) , which appear to manifest a survival response. Real-time RT-PCR performed on GIST-R RNA isolated after treatment with MP470 for 24 h with AXL-specific probes showed downregulation at the mRNA level by >100-fold (data not shown). This is likely owing to cytotoxic effects of MP470 on the GIST-R cells leading to an inhibition of AXL gene expression as cells approach impending cell death and/or downregulation to avoid further AXL receptor inhibition by MP470.
A conformational change in the ATP binding site of mutant c-Kit prevents IM binding The homology models of mutant c-Kit were based on 1T46 minimized at À629.8 kcal/mol and that based on 1PKG minimized at À568 kcal/mol. Ramachandran plots confirmed the correctness of the models. The homology models showed RMS deviations of 0.64 Å (1T46) (14) and 0.59 Å (1PKG) (15) from their respective crystal structures based on the C a backbone. Theoretical binding energies are shown for ATP, IM and MP470 (Table 4A and 
Discussion
GIST provides an opportunity to investigate mechanisms of resistance to IM therapy emerging in the clinic. We utilized an IM-sensitive human GIST cell line (GIST882) that expresses a mutated c-Kit (K642E), which was grown successfully at increasing concentrations of IM until resistance was achieved at 0.5 mM IM (GIST-R). GEP of the GIST-S versus GIST-R cells and two IM-resistant GIST patient biopsies demonstrated loss of Kit expression which was confirmed at the mRNA and protein levels. The lack of Kit expression on GIST-R cells provides an explanation for the mechanism of IM resistance. The GEP of GIST-S versus GIST-R or two IMresistant GIST patient biopsies showed AXL RTK to be overexpressed, which was confirmed by RT-PCR and Western blotting for the GIST cell lines. IHC analysis of the two IM-resistant GIST patients showed absence of c-Kit expression and strong AXL expression confirming and corroborating the cell culture data. Interactive docking with a homology model of the AXL kinase domain and the c-Met kinase domain demonstrated that IM did not bind these RTKs, thus providing an explanation for IM resistance. AXL (Greek word anexelekto or uncontrolled), a transforming gene, was isolated from patients with chronic myelogenous leukemia (CML) (O'Bryan et al., 1991) and is a member of a Ufo/AXL subfamily of RTKs that includes Mer/Nyk/ Eyk and Rse/Tyro3 (Chen et al., 1997) . It is a multidomain glycoprotein (896 amino acids) and consists of an extracellular region (425 amino acids) composed of two immunoglobulin-like domains and two fibronectin type III domains, a transmembrane a-helical domain and a c-terminal tyrosine kinase domain (Stitt et al., 1995) . AXL transduces signals from the ECM into the cytoplasm by binding to GAS-6 a g-carboxylated secreted protein that is sixfold overexpressed in GIST-R and is involved in the stimulation of cell proliferation by binding and activating AXL through an autocrine mechanism. This receptor can also mediate cell aggregation by homophilic binding (Cunningham et al., 1987) . c-Met, overexpressed and activated in numerous human carcinomas, binds to HGF which is 14-fold overexpressed in GIST-R cells and activates signaling in an autocrine manner (Michieli et al., 2004) . Both AXL and c-Met activate the same signaling pathways as c-Kit but the mechanism of regulation of these two RTK genes in GIST-R and potential signaling cross-talk remains to be elucidated.
The morphological change observed in the GIST-R cell line may play a role in defining an invasive phenotype; four gene products that may contribute to this process are described. GIST-R cells overexpress the chemokine CXCL14 (121-fold), which has been demonstrated to be overexpressed by tumor myoepithelial cells in the tumor microenvironment of breast cancer (Allinen et al., 2004) and may enhance their proliferation, migration and invasion by acting as a paracrine factor. However, in GIST-R cells CXCL14 appears to act as an autocrine growth factor. CD24, a cell surface receptor on B cells, is overexpressed in GIST-R cells (115-fold) and is involved in cell adhesion and metastatic spread in several cancers including ovarian, breast, non-small-cell lung, prostate and pancreas and is associated with a more aggressive course of cancer (Kristiansen et al., 2004) . SERPINE2 is a secreted ECM protease inhibitor that enhances the local invasiveness of cancers and is overexpressed (54-fold) in GIST-R cells (Buchholz et al., 2003) . Accumulating evidence suggests that the interplay of extracellular proteases and their inhibitors in invasion and metastasis is complex and extends beyond their roles as protease inhibitors (Andreasen et al., 2000) . The Wnt signaling pathway modulates the ECM in some human tumors. In the canonical pathway b-catenin activates transcription of the BAMBI, which is overexpressed in GIST-R cells (42.5-fold). Overexpression of BAMBI inhibits the response of tumor cells to TGF-b and suggests that bcatenin interferes with TGF-b-mediated growth arrest by inducing the expression of BAMBI (Sekiya et al., 2004) that may contribute to an invasive GIST phenotype. Acquired mutations leading to IM resistance involve mis-sense mutations in the kinase domain of c-Kit, including Thr670Ile, Tyr823Asp and Val654Ala (Chen et al., 2005; McLean et al., 2005) that are sensitive to PKC412, a novel tyrosine kinase inhibitor (DebiecRychter et al., 2005) . A study of 31 GIST patients were treated with IM and then underwent surgery: 13 were sensitive to IM, three had primary resistance and 15 had acquired resistance after initial benefit. There were no secondary mutations in Kit or a-PDGFR in the sensitive or primary resistance groups. However, secondary mutations were found in seven of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11. Most secondary mutations were located in KIT exon 17 (Antonescu et al., 2005) . Our mutant KIT homology model (Val654Ala) showed that IM does not bind but MP470 and ATP do, with tight binding interactions. An alternate homology model of mutant KIT kinase domain (Val654Ala) based on the insulin RTK and Abl kinase showed that disruption of IM binding is due to lack of hydrophobic contacts with the diaminophenyl ring of IM (McLean et al., 2005) . Our homology model, based on two c-Kit crystal structures, bound to ATP and not IM. However, MP470 bound tightly to both the WT and mutant KIT (Val654Ala) and has the potential to overcome secondary acquired mutations in GIST patients. Also it appears to be a putative AXL tyrosine kinase inhibitor (Figure 3b and c) .
Conventional chemotherapy drugs have been ineffective in treatment of GIST. We show that GIST-S cells are resistant to docetaxel alone but in combination with MP470 are sensitive to synergistic cell killing. Docetaxel inhibits tumor growth by induction of microtubule stabilization, promotion of BCL-2 phosphorylation and inactivation leading to p53-and p21-driven apoptosis (Haldar et al., 1997; Wang et al., 1999) . As GIST patients overexpress BCL-2 (80%), the strategy of targeting KIT/AXL and BCL-2 together appears feasible.
In GIST, the majority of gain-of-function mutations in KIT and/or a-PDGFR are outside the kinase domain (Duffaud and Blay, 2003) . The GIST882 cell line with an exon 13 mutation (K642E) is IM-sensitive. Although this is an uncommon mutation, it is predicted that the molecular mechanisms of IM resistance described here will be applicable to GIST with more common mutations. Therefore, novel therapies for IM-resistant GIST are urgently needed.
Materials and methods
Imatinib mesylate-resistant GIST882 cell line (GIST-R) The GIST882 cell line used in this study has a gain-of-function mutation in Kit (K642E) and is sensitive to IM, resulting in apoptosis with an IC 50 of 0.1-0.3 mM. The GIST882 cell line when exposed to IM for 4 days at 5 mM leads to cell death of 75-80% of cells, except for a population of B20-25% cells that remain viable at 4 days. The remaining cells were then harvested and grown in RPMI 1640 medium (HyClone no. SH30255.01), supplemented with 300 mg/l L-glutamine, 100 U/ ml penicillin, 100 mg/ml streptomycin and 15% fetal bovine serum (Gemini no. 100-106), and incubated in a humidified incubator at 371C with 5% CO 2 atmosphere. These cells were grown in IM at 0.1 mM until confluence. Half of the cells were frozen and the other half were then grown in 0.2 mM IM until confluence. Half of the resultant cells were frozen and the other half were grown in 0.3 mM to confluence. The 0.3 mM cell line was then grown to confluence in 0.5 mM IM. The above GIST cell lines were evaluated in an MTT assay for cell viability at IM concentrations varying from 0.05 to 50 mM.
Patient sample analysis
Two IM-resistant GIST patients had failed (per CAT scan, the tumor(s) had grown >20% from baseline using Response Evaluation Criteria for Solid Tumors criteria) after >2 months of treatment with IM at 800 mg orally daily. These two patients underwent debulking surgery and excess tissue was divided for paraffin and frozen sections. These biopsies were analysed by GEP, RT-PCR and IHC. Snap-frozen GIST patient samples were sectioned at 4 mm and fixed using acetone cooled to À201C for 10 min and allowed to dry. IHC was performed using a Discovery XT automated system (Ventana Medical Systems, Tucson, AZ, USA). The mouse monoclonal anti-Axl (MAB154, R&D Systems, MN, USA) antibody was used at 4 mg/ml. Paraffin blocks were routinely stained for c-Kit by IHC for diagnostic pathology. Biopsies were collected after obtaining informed consent through an IRB approved protocol.
Cell morphology analysis
All GIST cell lines were analysed for cell shape changes at post-confluence. Digital microscopy was utilized to capture changes in cell morphology.
Gene expression profiling and analysis GEP utilizing the human U133A Affymetrix (Santa Clara, CA, USA) genechip consisting of B22 000 'probe sets' was utilized to analyse the GIST-S (IM-sensitive), GIST-R (IM 0.5 mM) cell lines and two IM-resistant GIST patient biopsies. The GIST-R (0.5 mM IM) cell line was treated with MP470 (1 mM) for 6 and 24 h. Total RNA was extracted from GIST-S, GIST-R (0.5 mM IM) and MP470-treated GIST-R at 6 and 24 h utilizing the RNeasy Mini Kit (Qiagen, CA, USA) as described previously (Mahadevan et al., 2005b ).
Microarray quality control and generation of expression values
After hybridization, the quality of the data was tested with several methods. The arrays were first inspected visually for artifacts and B2 Oligo performance as per the manufacturer's instructions (Affymetrix, Inc. 'Gene Chip Expression Analysis Technical Manual', November 2004). Chip CEL files were then imported into R-BioConductor (v. 1.7) (http://genomebiology.com/2004/5/10/R80). MAS5 Present/Absent calls were generated with the simpleaffy (http://bioinformatics.picr.man.ac.uk/simpleaffy/) package using a target scaling factor of 100. The scale factors were within threefold of each other as recommended in the guidelines provided in the Affymetrix Gene Chip Expression Analysis: Data Analysis Fundamentals manual. The quality control metrics were generated using the 'qc' function provided in the simpleaffy package. All chips performed as follows: the average backgrounds decreased between 20 and 100, hybridization controls (bioB, bioC, bioD and cre) were all called present with increasing signal intensities and the 3 0 /5 0 ratios for the internal controls (GAPDH and b-actin) were less than 1.25 and 3 respectively. Further quality control was performed using the affyPLM package provided in the BioConductor suite. The microarray data was normalized by robust multichip analysis (RMA) using the 'fitPLM' function (default values). Chip pseudoimages of the weights and residuals, normalized unscaled standard error (NUSE) and relative log expression (RLE) values were used for chip-level quality assessment. Chip pseudoimages displayed no apparent artifacts that warranted excluding a chip from further analysis. NUSE and RLE plotting revealed the chips used in the experiments to be consistent. Next, both chips were normalized by RMA using the simpleaffy package. Log-fold changes were calculated from the normalized log 2 expression values.
Quantitative real time RT-PCR
To validate genes identified by GEP, quantitative real-time RT-PCR was performed on RNA isolated from GIST-S, GIST882 growing in 0.1, 0.2, 0.3 and 0.5 mM IM and two GIST patients who were IM-resistant. Furthermore, GIST-R growing in 0.5 mM IM was treated with MP470 at 1 mM for 6 and 24 h, and RNA was isolated for RT-PCR as described previously (Mahadevan et al., 2005a, b) . Moreover, RT-PCR was performed for AXL ligand GAS6 and c-Met ligand HGF to ascertain an autocrine mechanism of receptor activation.
Primer design PCR primers were designed using MacVector (Accelrys, San Diego, CA, USA) to produce amplicons with lengths ranging from 80 to 250 bp to optimize the efficiency of qPCR. Genes evaluated were KIT and AXL. The control b-actin from QuantumRNA b-Actin Internal Standards (Ambion, Austin, TX, USA) was used to normalize the qPCR data.
Immunoprecipitation and Western blot analysis GIST-S, GIST-R and MDA-MB-231 cells were grown in RPMI 1640 medium containing 15% FBS and 2 mM Lglutamine to confluence in 10 cm tissue culture plates. Three hundred microliters of boiling lysis buffer (1% SDS, 1.0 mM sodium orthovanadate, 10 mM Tris, pH 7.4) were added to each plate. Lysates were scraped into 1.5 ml microcentrifuge tubes and boiled for 5 min. DNA was sheared by passing lysates 3-4 times through a 25G needle. Lysates were then centrifuged at 20 000 g, 41C for 15 min. Supernatants were transferred to fresh 1.5 ml microcentrifuge tubes. Protein concentrations were determined with the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Three hundred micrograms of protein lysate were added to a 1.5 ml microcentrifuge tube. The volume was adjusted to 1 ml with Dulbecco's phosphate-buffered saline (DPBS). Ten micrograms of anti-c-Kit antibody (Santa Cruz, CA, USA) or anti-AXL antibody (MAB 1541, R&D Systems, MN, USA) were added to each tube. Tubes were gently rocked overnight at 41C. Pull down was performed for 1 h at 41C with Protein A agarose (Sigma no. P5906, St Louis, MO, USA). Precipitates were washed five times with cold DPBS. Agarose beads were re-suspended in 75 ml Laemmli sample buffer boiled for 5 min and then centrifuged at 20 000 g for 30 s. Seventy microliters of sample per well were loaded on a 1.5 mm 5% SDS miniacrylamide gel. The samples were transferred to nitrocellulose membrane (Tris/glycine buffer plus 20% methylhydroxide, 0.5% SDS, 30 mA, 16 h) at room temperature. After washing, membranes were incubated with TTSB, 0.3% teleost gelatin for 2 h at room temperature, washed, then incubated in 2 mg/ml primary antibody (rabbit anti-c-kit, Santa Cruz: no. sc-168) for 1 h at room temperature. Secondary antibody at a 1:5000 dilution (IRDye 800 donkey anti-rabbit, Rockland Immunochemicals, Gilbertsville, PA, USA) was used to visualize bands with a LI-COR Odyssey Infrared Imaging System.
Phosphorylation status of c-Kit and AXL in GIST and MDA-DB-231 cells treated with IM and MP470 For detection of phosphorylated c-Kit and AXL, GIST and MDA-DB-231 cells were lysed with lysis buffer, and loaded onto a phosphoprotein-purification column (Qiagen) and eluted. Samples were run on SDS-PAGE, transferred to nitrocellulose filters. Western blotting was performed with cKit receptor-or AXL receptor-and phosphor-specific antibody (Santa Cruz) to determine the tyrosine phosphorylation status in the absence and presence of drug (in GIST cells IM or MP470,) or MDA-MB-231 cells (0.0, 0.1, 1.0, 10 mM; MP470) after 30 min and compared to controls. The results were analysed on a Li-Cor Phosphoimager (Li-Cor Systems).
Cellular cytotoxicity assays
GIST-S and GIST-R cells were plated onto a 96-well plates at the adequate density to reach B80% confluency at the end of assay. After overnight incubation the cells were exposed to IM (0.05-50 mM) or MP470 (0.25-11 mM) for 4 days. All studies were performed in triplicate and were repeated three different times. After incubation, 20 ml of 2 mg/ml MTT were added to each well and incubated for additional 4 h. The media and MTT dye was aspirated, and 100 ml dimethyl sulfoxide (DMSO) was added to each well; absorbance was read at 540 nm on a plate reader (Wallac Victor, PerkinElmer, Wellesley, MA, USA). Data were expressed as the percentage survival of control calculated from the absorbance, corrected for background.
GIST-R was grown to B80% confluence and treated with different concentrations of taxotere (0.075-20 mM) in the presence of 1 mM MP470 or with different concentrations of MP470 (0.01-50 mM) with 1.0, 0.1 and 0.01 mM taxotere for 4 days. MTT addition and data analysis were performed as above.
Homology modeling and interactive docking
The crystal structures of the WT tyrosine kinase domain of Kit bound to IM (PDB: 1T46) (Mol et al., 2004) and ATP (PDB: 1PKG) (Mol et al., 2003) were utilized as templates for homology modeling of the Val654Ala mutation (Chen et al., 2004) . Interactive docking studies were conducted (FlexX, Tripos Inc., St Louis, MO, USA) to correlate any structural changes before and after introducing the mutation. Modeler (version 7.0) was utilized for model building, and the model was energy minimized using Sybyl 7.0, Tripos. The correctness of the model was verified by analysing the Ramachandran plot. A homology model of the human AXL tyrosine kinase was constructed utilizing the crystal structure of the IGF-1 receptor kinase domain (PDB: 1JQH) (Pautsch et al., 2001 ) based on top hits observed when the AXL TK domain was input into PSI-PHI BLAST (NCBI) and 3D-PSSM (Kelley et al., 2000) . The model was refined and structural correctness confirmed with PROCHECK (Laskowski et al., 1993) . The crystal structure of cMet (PDB: 1ROP) (Schiering et al., 2003) was downloaded and ATP, IM and MP470 were interactively docked utilizing FlexX (Sybyl 7.0, Tripos Inc., St Louis, MO, USA).
